Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Of Combination Chemotherapy And Surgical Resection In The Treatment Of Adrenocortical Cancer: Mitotane And Continuous Infusion Doxorubicin, Vincristine And Etoposide With The P-Glycoprotein Antagonist, Tariquidar (XR9576), Before And After Surgical Resection.

Trial Profile

A Study Of Combination Chemotherapy And Surgical Resection In The Treatment Of Adrenocortical Cancer: Mitotane And Continuous Infusion Doxorubicin, Vincristine And Etoposide With The P-Glycoprotein Antagonist, Tariquidar (XR9576), Before And After Surgical Resection.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2012

At a glance

  • Drugs Tariquidar (Primary) ; Doxorubicin; Etoposide; Mitotane; Vincristine
  • Indications Adrenal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 27 Feb 2012 Actual initiation date changed from Dec 2004 to Oct 2003 as reported by ClinicalTrials.gov.
    • 27 Feb 2012 Actual initiation date changed from Dec 2004 to Oct 2003 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top